BioLineRx Ltd.
BLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $4 | $1 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $4 | $1 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 502.9% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 68% | 23.1% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 13.5% | -1,189.3% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -31.9% | -1,262.8% | – | – |
| EPS Diluted | -0.12 | -0.94 | -0.48 | -0.61 |
| % Growth | 87.2% | -95.8% | 21.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |